ZA857610B - Hepatitis b antigenic compositions and vaccines against hepatitis b derived therefrom - Google Patents

Hepatitis b antigenic compositions and vaccines against hepatitis b derived therefrom

Info

Publication number
ZA857610B
ZA857610B ZA857610A ZA857610A ZA857610B ZA 857610 B ZA857610 B ZA 857610B ZA 857610 A ZA857610 A ZA 857610A ZA 857610 A ZA857610 A ZA 857610A ZA 857610 B ZA857610 B ZA 857610B
Authority
ZA
South Africa
Prior art keywords
hepatitis
particles
hbsag
derived therefrom
vaccines against
Prior art date
Application number
ZA857610A
Other languages
English (en)
Inventor
Alfred Mayer Prince
John Vnek
Original Assignee
New York Blood Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24634769&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA857610(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by New York Blood Center Inc filed Critical New York Blood Center Inc
Publication of ZA857610B publication Critical patent/ZA857610B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA857610A 1984-10-02 1985-10-02 Hepatitis b antigenic compositions and vaccines against hepatitis b derived therefrom ZA857610B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/656,833 US4639371A (en) 1984-10-02 1984-10-02 Hepatitis B antigenic compositions and vaccines against hepatitis B derived therefrom

Publications (1)

Publication Number Publication Date
ZA857610B true ZA857610B (en) 1986-06-25

Family

ID=24634769

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA857610A ZA857610B (en) 1984-10-02 1985-10-02 Hepatitis b antigenic compositions and vaccines against hepatitis b derived therefrom

Country Status (10)

Country Link
US (1) US4639371A (de)
EP (1) EP0177015B1 (de)
JP (1) JPH0832636B2 (de)
KR (1) KR900006887B1 (de)
CN (1) CN1016315B (de)
AT (1) ATE77055T1 (de)
AU (1) AU599007B2 (de)
CA (1) CA1265447A (de)
DE (1) DE3586193T2 (de)
ZA (1) ZA857610B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935235A (en) * 1979-05-24 1990-06-19 The Regents Of The University Of California Non-passageable viruses
DE3176404D1 (en) * 1980-04-22 1987-10-08 Pasteur Institut Vaccine against viral hepatitis b, method and transformed eucaryotic cells for the preparation of this vaccine
US4695454A (en) * 1985-04-01 1987-09-22 New York Blood Center, Inc. Process for preparing hepatitis B surface antigen containing particles in novel forms which are highly immunogenic
US4816564A (en) * 1986-01-31 1989-03-28 Merck & Co., Inc. Method for producing hepatitis B virus proteins in yeast
DE10299017I2 (de) * 1987-06-22 2005-05-25 Medeva Holdings Bv Hepatitis-B-Oberfl{chenantigen enthaltendes Peptid.
US4855055A (en) * 1988-09-28 1989-08-08 National Science Council Isolation and purification pre-S2 containing hepatitis B virus surface antigen by chemical affinity chromatography
US5462863A (en) * 1989-02-09 1995-10-31 Development Center For Biotechnology Isolation of Hepatitis B surface antigen from transformed yeast cells
IL97985A0 (en) * 1990-05-07 1992-06-21 North American Vaccine Inc Improved vaccine compositions
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
EP0491077A1 (de) * 1990-12-19 1992-06-24 Medeva Holdings B.V. Zusammensetzung verwendbar als therapeutisches Mittel gegen chronische virale Leberkrankheiten
WO2007041285A2 (en) * 2005-09-29 2007-04-12 Viral Genetics, Inc. Complexes of inactivated pepsin fraction and heat shock protein
CN104628830A (zh) * 2015-01-23 2015-05-20 深圳康泰生物制品股份有限公司 重组酿酒酵母表达HBsAg的制备工艺及其分离纯化工艺、HBsAg和乙肝疫苗

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3636191A (en) * 1969-10-08 1972-01-18 Cancer Res Inst Vaccine against viral hepatitis and process
US3735004A (en) * 1971-11-01 1973-05-22 Us Army Hepatitis vaccine
US3951937A (en) * 1973-12-20 1976-04-20 The Community Blood Council Of Greater New York, Inc. Large scale purification of hepatitis type B antigen using polyethylene glycol
JPS5523253B2 (de) * 1973-12-28 1980-06-21
JPS5523254B2 (de) * 1974-01-28 1980-06-21
SE437329B (sv) * 1975-03-14 1985-02-25 Community Blood Council Sett att ur blodserum framstella vaccin mot virushepatit
US4164565A (en) * 1975-03-14 1979-08-14 New York Blood Center, Inc. Vaccine for active immunization containing hepatitis B surface antigen and associated antigen
US4017360A (en) * 1975-05-14 1977-04-12 Merck & Co., Inc. Method for purifying hepatitis B antigen
US4113712A (en) * 1976-03-08 1978-09-12 The Green Cross Corporation HBsAG Particle composed of single polypeptide subunits and the preparation procedure
US4118477A (en) * 1977-02-14 1978-10-03 Merck & Co., Inc. Hepatitis B antigen
US4181713A (en) * 1978-10-30 1980-01-01 Merck & Co., Inc. Isolation of HBs Ag
US4442205A (en) * 1981-09-22 1984-04-10 The United States Of America As Represented By The Department Of Health And Human Services Simian virus recombinant that directs the synthesis of hepatitis B surface antigen
US4490361A (en) * 1983-12-02 1984-12-25 Alpha Therapeutic Corporation Virus inactivating heat treatment of plasma fractions
NL8401066A (nl) * 1984-04-04 1985-11-01 Stichting Centraal Lab Werkwijze ter bereiding van preparaten, die de humorale en cellulaire immuunreaktiviteit vergroten.

Also Published As

Publication number Publication date
EP0177015A2 (de) 1986-04-09
JPS61191621A (ja) 1986-08-26
AU599007B2 (en) 1990-07-12
US4639371A (en) 1987-01-27
DE3586193D1 (de) 1992-07-16
EP0177015A3 (en) 1988-01-13
ATE77055T1 (de) 1992-06-15
DE3586193T2 (de) 1993-01-07
CN85106376A (zh) 1987-03-04
CA1265447A (en) 1990-02-06
EP0177015B1 (de) 1992-06-10
AU4817885A (en) 1987-04-09
KR900006887B1 (ko) 1990-09-24
CN1016315B (zh) 1992-04-22
KR860003336A (ko) 1986-05-23
JPH0832636B2 (ja) 1996-03-29

Similar Documents

Publication Publication Date Title
ZA857610B (en) Hepatitis b antigenic compositions and vaccines against hepatitis b derived therefrom
DE3176404D1 (en) Vaccine against viral hepatitis b, method and transformed eucaryotic cells for the preparation of this vaccine
ES8705036A1 (es) Procedimiento para preparar una vacuna que comprende un polipeptido fijado a una membrana
IL86650A0 (en) Animal derived cells and liposomes,having an antigenic protein incorporated into their membrane
DE3280284D1 (de) Herstellung von oberflaechen-hepatitis-b-antigen in hefe.
WO1997001640A3 (en) Vaccines against hepatitis c
GB9808932D0 (en) Polyepitope carrier protein
KR950701822A (ko) 간염B 표면 항원 및 다른 항원으로 구성된 조합 백신(Combined vaccines comprising hepatitis B surface antigen and other antines)
ES8608883A1 (es) Procedimiento de preparacion de un conjugado de muramilpeptido y de un hapteno o fragmento haptenico de bajo peso molecular.
HUT35521A (en) Process for preparing a pharmaceutical composition containing a purified, detixicated endotoxine and a pyridine soluble extract of a microorganism
PT74246B (en) Process for preparing hbsag
CA2099707A1 (en) Haemophilus somnus outer membrane protein extract enriched with iron-regulated proteins
EP0250253A3 (de) T- und B-Zellepitopen des pre-S-Gebietes des Hepatitis-B-Oberflächenantigens
ZA861767B (en) Process for preparing hepatitis b surface antigen containing particles in novel forms which are highly immunogenic
ZA873922B (en) Method of preparation and use for feline leukemia virus antigens
EP0414816A4 (en) Induction of tolerance to a foreign antigen
DE3269188D1 (en) Vaccine for hepatitis
PL339366A1 (en) Polypeptides of hepatitis b virus
PT69953A (en) Process for preparing a composition comprising a lyophilized herpes virus
DK645687A (da) Fremgangsmaade til fremstilling af en vaccine mod hepatitis b og den opnaaede vaccine
GR3021983T3 (en) Cross-reactive influenza a immunization
EP0290246A3 (de) Impfstoff zur Erzeugung einer gegen Tollwutvirus schützenden immunogenen T-Zellen-Respons
ATE159758T1 (de) Azelluläre impfstoffe
IT1246322B (it) Procedimento per la preparazione di farmaci per la cura dell'epatite bcaratterizzato dal fatto di identificare il recettore della transferrina come struttura di membrana responsabile dell'infezione; e farmaci cosi' ottenuti.
Vornovitskii et al. Methods for Dilatometric Investigations of Welding Slags